Objectives. To describe adherence to recommendations for TNFa blocker (TNFb) initiation and continuation in early axial Spondyloarthropathy (axSpA); and to evaluate the impact of adherence to these recommendations over 5 years of follow-up in the DEvenir des Spondyloarthrites Indiffé rencié es Ré centes (DESIR) cohort.
Introduction
Spondyloarthropathy (SpA) is a chronic inflammatory disease that can present with different phenotypes, namely with axial SpA (axSpA) [1] or peripheral manifestations (peripheral SpA) [2] . In addition, the presence or absence of structural damage of the sacroiliac joints on X-rays (i.e. radiographic sacroiliitis) allows the classification of a patient into one of two main groups: patients with radiographic sacroiliitis (i.e. radiographic axSpA, r-axSpA) or without radiographic sacroiliitis (non-radiographic axSpA, nr-axSpA) [1] .
NSAIDs are the cornerstone in the treatment. Nevertheless, the major recent advance in SpA treatment has been the use of TNFa blockers (TNFbs) [1, 3] , which have proven to quickly reduce axial inflammatory symptoms and signs in axSpA patients in several randomized clinical trials [414] .
According to both the first Assessment of SpondyloArthritis International Society (ASAS) recommendations for TNFb use in radiographic axSpA (r-axSpA) published in 2003 and the 2006 update [15, 16] , TNFbs should be initiated in patients with a definite diagnosis of r-axSpA [usually identified by the fulfilment of the modified New York (mNY) criteria] [17], presenting with an active disease and a positive expert's opinion, despite NSAID treatment. Also, these recommendations suggest consideration of discontinuation of TNFb treatment in the case of insufficient response after 612 weeks of treatment.
The 2010 update [18] of these recommendations included the major change that not only r-axSpA patients could be treated with TNFb, but also all patients fulfilling the ASAS axial SpA criteria, and the previous NSAID treatment duration was shortened.
In the most recent update (2016) [19] , no major changes were included with regard to TNFb initiation in axSpA patients, but (for the first time) an active disease could be defined either by a BASDAI or by an Ankylosing Spondylitis Disease Activity Score (ASDAS).
Finally, the marketing authorization for the initiation of TNFbs by the European Medicines Agency (EMA) includes either severe r-axSpA with inadequate response to conventional therapy, or severe non-radiographic axSpA but with objective signs of inflammation. (Supplementary  Table S1, available However, we know that a gap exists between recommendations and their implementation in clinical practice: potentially, neither all patients meeting the conditions for TNFb initiation will be prescribed a TNFb, nor all patients for whom a TNFb is prescribed will fully meet these conditions. To date, there are some reported studies in RA that conclude that 22.8% of patients adhere to treatment recommendations (concerning DMARDs therapy) [20] . However, there is no data regarding the adherence to TNFb recommendations for ax-SpA management in daily clinical practice, nor for the long-term impact of such adherence.
These preliminary remarks prompted us to conduct this study aiming: to describe adherence to the 2003/ 2006 ASAS, 2016 ASAS/EULAR and EMA recommendations for TNFb initiation and its impact on functional disability, quality of life and sick-leave days over 5 years of follow-up; to describe adherence to the 2003/2006 ASAS and 2016 ASAS/EULAR recommendations for TNFb continuation and its impact on functional disability, quality of life and sick-leave days over 5 years of follow-up.
Methods

Study design
Data from the DESIR cohort (NCT01648907), the French prospective cohort of patients with early inflammatory back pain suggestive of axSpA was used [21] . Visits were scheduled every 6 months during the first 2 years and yearly thereafter. The present study analyses only the first 5 years of follow-up, and for the study we obtained the approval of the 'Comité pour la Protection des Personnes Physiques (CPP) île de France III' ethical committee. All participants gave their written informed consent.
Patients
A total of 708 patients aged >18 and <50 years old with early inflammatory back pain (>3 months but <3 years) suggestive of ax-SpA were included in this study. Previous biologic treatment was an exclusion criterion of the cohort; therefore, no patient had been exposed to TNFbs at baseline. Patients who received a biologic agent other than a TNFb as the first biologic treatment were also excluded. The dataset used for this study was locked on 15 June 2016.
Visits definition
TNFbs could be initiated at any time during the follow-up, according to a patient's rheumatologist's decision, including between two visits. In order to evaluate the criteria fulfilment for TNFb initiation according to recommendations for TNFb initiation, V0 was defined as the last visit available before TNFb initiation. Adherence to recommendations for TNFb initiation (i.e. whether a patient who met the conditions for initiating a TNFb at V0 had indeed received a TNFb) was evaluated at the first available visit following V0 (i.e. at the V1 visit); when this visit occurred at least 12 weeks after TNFb initiation, evaluation of whether the patient met the conditions for continuing TNFb treatment was also conducted at this visit. Finally, adherence to recommendations for TNFb continuation (e.g. whether a patient who met the conditions for continuing a TNFb at the V1) was evaluated at the next available visit, i.e. V2.
For patients not receiving TNFb therapy during the 5 years of follow-up, we checked whether they had met the conditions for initiating a TNFb at any visit. For patients who did, this visit was considered V0; for patients who did not, any visit could be considered V0. For patients/visit balance concerns, we decided to look at the distribution of V0 across patients commencing TNFb therapy and to attribute V0 proportionally for patients who did not (e.g. for 162 patients who commenced a TNFb, V0 was the inclusion visit; so, we considered the inclusion visit as V0 for 162 patients who did not commence the therapy).
Data collection
Socio-demographics included age, gender, highest degree of education, centre of inclusion (with 530 patients including in DESIR cohort), smoking status and days of sick leave between each visit. Regarding disease characteristics, ASAS and mNY criteria [17, 22] , presence of inflammatory lesions on MRI, HLA-B27 status, level of confidence of the Rheumatologist 57 (010 scale) in the axSpA diagnosis, abnormal CRP (defined as 56 mg/dl) and NSAIDs intake were collected. Disease activity was assessed by the BASDAI, ASDAS [23] and the BAS-G [24] . Disease severity was evaluated by the BASFI [25] and BASMI [26] . We assessed quality of life through the Short Form-36 (SF-36) [27] .
Assessment of recommendations
A description of the different sets of recommendations and their equivalence to the variables collected in DESIR is presented in supplementary Table S2 , available at Rheumatology online.
Regarding recommendations for TNFb initiation, 2003/ 2006 ASAS recommendations propose that therapy should be initiated in patients with: definite diagnosis of radiographic axSpA according to the mNY criteria, AND presenting with an active disease for at least 4 weeks, defined by a BASDAI 5 4 (on a 010 scale), AND a positive expert's opinion, AND despite conventional therapy (failure of at least two NSAIDs over a 3 months' period at maximum recommended dose unless contraindicated was mandatory). According to the ASAS/EULAR 2016 recommendations for TNFb initiation, these drugs should be initiated in patients with: objective abnormalities of the sacroiliac joints (either according to the mNY OR MRI sacroiliitis) OR elevated CRP, AND NSAID inefficacy (at least two NSAIDs over 4 weeks at maximum recommended dose), AND presenting with an active disease for at least 4 weeks, defined by a BASDAI 5 4 (in a 010 scale) OR by ASDAS 5 2.1, AND a positive expert's opinion. Finally, according to EMA recommendations for TNFb initiation, therapy should be initiated in patients with: severe AS with inadequate response to conventional therapy OR severe non-radiographic axSpA with objective signs of inflammation (defined by elevate CRP and/or MRI).
Regarding recommendations for TNFb continuation, 2003/2006 ASAS recommendations propose that therapy should be continued in patients with: a BASDAI 50% relative change OR an absolute change of 20 points (0100 scale) after 612 weeks of treatment. According to the 2016 ASAS/ EULAR recommendations for TNFb continuation, these drugs should be continued in patients with: an ASDAS improvement 5 1.1 OR a BASDAI improvement 5 2 (0100 scale) after at least 12 weeks of treatment.
Handling of missing data
All missing information was carried forward from the previous visit, except for longitudinal outcomes, which were estimated by mixed-model estimation. For imaging variables, missing information was considered to be negative.
Statistical analysis
First, a description of the use of TNFbs over the first 5 years of follow-up at each DESIR cohort visit and the baseline characteristics of groups of patients commencing/not commencing TNFb therapy was performed.
The percentages of patients meeting the conditions for TNFb initiation according to ASAS 2003 ASAS /2006 ASAS , 2016 and EMA recommendations within the group of patients commencing TNFb therapy, and also within the group of patients not commencing TNFb therapy, were calculated. We evaluated the percentage of patients adherent to each recommendation for TNFb initiation: a patient was considered adherent to recommendations if he/she met the conditions for initiating a TNFb (at V0) and who commenced TNFb therapy between V0 and V1, or if he/ she did not meet the conditions for TNFb initiation at V0 and did not commence TNFb therapy between V0 and V1. Identification of the predictive factors for the adherence to each TNFb initiation recommendation were explored first by univariable analysis (Chi-square and t test, as appropriate), and thereafter by multivariate logistic regression, including in the model variables selected by the univariate analysis (when P 4 0.20). Finally, we explored the impact of adherence to each recommendation for TNFb initiation by estimating disease severity (i.e. BASFI), quality of life and days of sick leave over 5 years by mixed models with random effects (here, the subject) and including in the model 'adherence' as the fixed independent variable.
Regarding recommendations for TNFb continuation, the percentage of patients meeting the conditions for TNFb continuation at V1 (according to ASAS 2003/2006 and 2016 recommendations) within the group of patients who commenced TNFb therapy were calculated. We evaluated the percentage of patients adherent to each recommendation for TNFb continuation: a patient was considered adherent if at V1 he/she met the conditions for continuing TNFb therapy and at the following visit (V2) he/she was still on TNFb therapy, but also if he/she did not meet the conditions for continuing at V1 and at V2 TNFb treatment had been discontinued. Identification of the predictive factors for the adherence to each TNFb continuation recommendation were explored first by univariable analysis (Chi-square and t test, as appropriate), and thereafter by multivariate logistic regression, including in the model variables selected by the univariate analysis (when P 4 0.20). Finally, we explored the impact of adherence to each recommendation for TNFb continuation by estimating disease severity (i.e. BASFI), quality of life and days of sick leave over 5 years by binomial mixed models with random effects (here, the subject) and including in the model 'adherence' as the fixed independent variable.
The data were analysed using the software SPSS 20.0 version and R version 3.2.3.
Results
Of the 708 patients included in the analysis, a total of 258 (36.44%) patients commenced TNFb therapy over the first 5 years of follow-up. A flow chart is presented in Fig. 1 .
Demographics and disease characteristics of all patients at inclusion in the cohort are presented in Table 1 .
Recommendations for TNFb initiation Baseline demographic and disease characteristics with regard to recommendations adherence are represented in Table 2 and supplementary Table S3 The impact of adherence to recommendations for TNFb initiation over 5 years of follow-up is represented in Table 3  and in supplementary Table S4, available 
Discussion
This is, to our knowledge, one of the first studies aiming to evaluate adherence to recommendations for TNFb management in axSpA in daily clinical practice. These results highlight that a gap does indeed exist between the recommendations and their implementation in clinical practice. However, even though in our study 50% of patients were adherent to recommendations in the early axSpA population, both for initiation and continuation of TNFb, those patients had greater long-term functionality, quality of life and functional and employment/economic benefits compared with non-adherent patients. The frequency of adherence to recommendations in these SpA patients was not particularly high, taking into account the importance of these drugs in terms of costs and health impact. Nevertheless, the percentage was higher than in some reported studies in RA, in which it was concluded that 22.8% of patients from the SPOIR cohort adhered to treatment recommendations (concerning DMARDs therapy); however, in the Etude et Suivi des POlyarthrites Indiffé rencié es Ré centes (ESPOIR) cohort, recommendations adherence differed between centres, ranging from 11.4 to 40.3% [20] . One possible explanation regarding these percentages in SpA vs RA patients is that recommendations for DMARDs management in RA include a wider range of drugs and several treatment steps, which make them more challenging in terms of adherence [28] .
Regarding the suitability of the recommendations for TNFb initiation, 2016 seem to better discriminate patients who can benefit from these treatments. ) ; thus, the majority of them did not initiate treatment because they did not meet the conditions for initiation. Interestingly, some baseline socio-demographic characteristics were strongly associated with adherence to recommendations for TNFb initiation: that is, being a male and having a higher level of education. These results are similar to those reported in previous studies in the DESIR cohort, in which these two characteristics are associated with stable low or improving disease activity trajectories [29] . In addition, male sex has been reported as a factor associated with better treatment adherence [30] . This may be a patient profile with greater likelihood of good response to treatment and, therefore, with greater adherence to the recommendations.
Recent reported studies showed that productivity loss costs among DESIR patients still represented between 10 and 17% of annual costs, and the most significant cost component was biologic drugs [31] . In our study, being in accordance with ASAS 2003/2006 and 2016 recommendations had a significant impact on employment and economic costs. That is to say, in spite of the higher cost of the biologic treatment in patients who adhered to the recommendations, selection of patients for the initiation of TNFb therapy according to the recommendations reduces days of sick leave and, as a consequence, potentially productivity loss costs.
Our study had some limitations but also several strengths. One limitation was that TNFb treatment could be initiated at any time by the treating rheumatologist, independent of DESIR's visits, which can also implicate a variance in treatment duration between patients. However, by setting the study visits (i.e. V0, V1 and V2) and performing a mixed model with random effects, we reduced the variance across treatment duration at the time of evaluation and the variance of the impact at 5 years of follow-up. Furthermore, these intervals reflect real life, in which it is difficult to evaluate treatment effect at precisely 12 weeks of TNFb therapy, due to time constraints. Another limitation was that the fulfilment of recommendations was not included in the DESIR's case report form; however, recommendations were evaluated for each patient through the combination of different variables, and all of them were available in the DESIR database.
The main strength of our study is that it is the first to evaluate the implementation of recommendations for the management of TNFb use in patients with ax-SpA in daily clinical practice over 5 years of follow-up, and analyses its impact regarding functional outcomes.
In conclusion, this study demonstrates that adherence to recommendations in the initiation and continuation of TNFb therapy leads to better long-term outcomes in terms of quality of life and sick leave.
